Prescient’s clinical trial goes from strength to strength, with recruitment expanded for its PTX-100 cancer study
Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it...
Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it...
Prescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its drug PTX-100 in...
Cancer results from the mutation of normal cells to tumour cells because of interaction between...
Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in...
ASX-listed biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) is leaving no stone unturned as it progresses towards...
Investors have plenty of exciting updates to look forward as PTX advances clinical trials and...
Auspiciously January 2022 will go down as the first month investing for the Merchant Biotech...
New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use...
Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of...
A new longitudinal study of cancer patients treated with a revolutionary type of cell therapy...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.